155 related articles for article (PubMed ID: 34967360)
41. Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion.
Matsushima R; Noma H; Yasuda K; Goto H; Shimura M
J Ocul Pharmacol Ther; 2019 Sep; 35(7):407-412. PubMed ID: 31373873
[No Abstract] [Full Text] [Related]
42. Ranibizumab for macular edema secondary to retinal vein occlusion: a meta-analysis of dose effects and comparison with no anti-VEGF treatment.
Song WT; Xia XB
BMC Ophthalmol; 2015 Mar; 15():31. PubMed ID: 25881069
[TBL] [Abstract][Full Text] [Related]
43. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
[TBL] [Abstract][Full Text] [Related]
44. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
Wolf-Schnurrbusch UE; Ghanem R; Rothenbuehler SP; Enzmann V; Framme C; Wolf S
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3334-7. PubMed ID: 21087958
[TBL] [Abstract][Full Text] [Related]
45. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
Spooner K; Hong T; Fraser-Bell S; Chang AA
Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
[TBL] [Abstract][Full Text] [Related]
46. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial.
Gurudas S; Patrao N; Nicholson L; Sen P; Ramu J; Sivaprasad S; Hykin P
JAMA Ophthalmol; 2022 Feb; 140(2):143-150. PubMed ID: 34989804
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Each Retinal Layer Thicknesses between Eyes with Central Retinal Vein Occlusion and Normal Contralateral Eyes.
Yu HY; Lee MW; Kim JT; Lee SC; Lee YH
Korean J Ophthalmol; 2022 Jun; 36(3):274-281. PubMed ID: 35527524
[TBL] [Abstract][Full Text] [Related]
48. Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
Osaka R; Muraoka Y; Miwa Y; Manabe K; Kobayashi M; Takasago Y; Ooto S; Murakami T; Suzuma K; Iida Y; Tsujikawa A
Ophthalmologica; 2018; 239(1):27-35. PubMed ID: 28946138
[TBL] [Abstract][Full Text] [Related]
49. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.
Im JHB; Jin YP; Chow R; Dharia RS; Yan P
Surv Ophthalmol; 2022; 67(6):1593-1602. PubMed ID: 35970234
[TBL] [Abstract][Full Text] [Related]
50. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
[TBL] [Abstract][Full Text] [Related]
51. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
[TBL] [Abstract][Full Text] [Related]
52. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
Gokce G; Sobaci G; Durukan AH; Erdurman FC
Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
[TBL] [Abstract][Full Text] [Related]
53. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review.
Pielen A; Feltgen N; Isserstedt C; Callizo J; Junker B; Schmucker C
PLoS One; 2013; 8(10):e78538. PubMed ID: 24205253
[TBL] [Abstract][Full Text] [Related]
55. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion.
Ip MS; Gottlieb JL; Kahana A; Scott IU; Altaweel MM; Blodi BA; Gangnon RE; Puliafito CA
Arch Ophthalmol; 2004 Aug; 122(8):1131-6. PubMed ID: 15302652
[TBL] [Abstract][Full Text] [Related]
56. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
Kamei M; Terasaki H; Yoshimura N; Shiraga F; Ogura Y; Grotzfeld AS; Pilz S; Ishibashi T
Acta Ophthalmol; 2017 Feb; 95(1):e29-e35. PubMed ID: 27654837
[TBL] [Abstract][Full Text] [Related]
57. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
58. [The use of anti-angiogenic drugs for central retinal vein occlusion].
Waisbourd M; Loewenstein A
Harefuah; 2010 Apr; 149(4):243-4, 261. PubMed ID: 20812499
[TBL] [Abstract][Full Text] [Related]
59. Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions.
Corazza P; D'Alterio FM; Savastano MC; Kabbani J; Duguid G; Savastano A; Younis S
Eur J Ophthalmol; 2022 Nov; 32(6):3536-3546. PubMed ID: 35253456
[TBL] [Abstract][Full Text] [Related]
60. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
